Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
暂无分享,去创建一个
Patrick Neven | Peter Van Loo | P. Neven | P. Van Loo | R. Paridaens | M. Christiaens | C. de Wolf‐Peeters | A. Smeets | Ann Smeets | Robert Paridaens | Marie-Rose Christiaens | I. Vanden Bempt | M. Drijkoningen | Isabelle Vanden Bempt | Maria Drijkoningen | Christiane De Wolf-Peeters | Peter Van Loo
[1] M. Ladanyi,et al. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. , 2003, The Journal of molecular diagnostics : JMD.
[2] M. J. van de Vijver,et al. Amplification and over-expression of the neu oncogene in human breast carcinomas. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[3] T. Henkel,et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy , 2007, Journal of Clinical Pathology.
[4] J. Inazawa,et al. Analysis of numerical aberrations in specific chromosomes by fluorescent in situ hybridization as a diagnostic tool in breast cancer , 1996, Cancer.
[5] F. Révillion,et al. ERBB2 oncogene in human breast cancer and its clinical significance. , 1998, European journal of cancer.
[6] V. L. Wilson,et al. Chromosome 17 aneusomy detected by fluorescence in situ hybridization in vulvar squamous cell carcinomas and synchronous vulvar skin. , 2000, The American journal of pathology.
[7] D. Hayes,et al. Heart of darkness: the downside of trastuzumab. , 2006, Journal of Clinical Oncology.
[8] T. Visakorpi,et al. Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.
[9] J. Bartlett,et al. Chromosome 17 Aneusomy is Associated with Poor Prognostic Factors in Invasive Breast Carcinoma , 2004, Breast Cancer Research and Treatment.
[10] Peter A Kaufman,et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.
[11] R. Walker,et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2005 .
[12] C. Sotiriou,et al. Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice , 2005, Clinical Cancer Research.
[13] K S Panageas,et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] T. Grogan,et al. The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast: A Fluorescent In Situ Hybridization, Immunohistochemical, and Isotopic mRNA In Situ Hybridization Study , 2005, The American journal of surgical pathology.
[15] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Mottolese,et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. , 2006, European journal of cancer.
[17] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[18] D. Slamon,et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] David Cameron,et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.
[20] A. Luini,et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. , 2007, European journal of cancer.
[21] S. Serrano,et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry , 2005, Breast Cancer Research.
[22] I. Ellis,et al. Method for grading breast cancer. , 1993, Journal of clinical pathology.
[23] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[24] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[25] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[26] Greg Yothers,et al. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.
[27] C. de Wolf‐Peeters,et al. Real‐time reverse transcription‐PCR and fluorescence in‐situ hybridization are complementary to understand the mechanisms involved in HER‐2/neu overexpression in human breast carcinomas , 2005, Histopathology.
[28] C. Sotiriou,et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer , 2006, Molecular Cancer Therapeutics.
[29] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[30] Jorma Isola,et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.
[31] D. Slamon,et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.
[32] K. Kim,et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer , 2007, Journal of Clinical Pathology.
[33] J. Winer,et al. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. , 1999, Analytical biochemistry.